Novavax Profit Margin

The latest profit margin for NVAX is -59.87% as of June 2026. That compares with 39.2% in the prior-year period — down 252.7% year over year. That is below the Healthcare sector average of 13.76%. Investors often review this figure alongside Novavax's historical trend and sector peers before judging valuation or financial health.

Over the past year, NVAX's profit margin moved from 39.2% to -59.87% — a 252.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novavax's valuation or profitability profile.

Against Healthcare companies, NVAX currently prints -59.87% for profit margin, while the sector average sits near 13.76%. That is roughly 535.1% below the sector mean. Large gaps often invite a closer look at Novavax's growth, margins, and balance sheet.

Profit Margin shows how effectively Novavax converts resources into returns. At -59.87%, NVAX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 39.2% in the prior-year period — down 252.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NVAX's profit margin (-59.87%), review year-over-year change from 39.2%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.